Trends in hepatitis C treatment uptake in the United States

Hepatology

Volumn 60, Issue 2, 2014, Pages 768-769

  Clark, Paul J ^a   Thompson, Alexander J ^a   Patel, Keyur ^a   Muir, Andrew J ^a   Volk, Michael L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG UTILIZATION; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

ANTIVIRAL AGENTS; DRUG APPROVAL; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES;

EID: 84904731863     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27213     Document Type: Article

References (2)

1. Volk ML, Tocco R, Saini S, Lok ASF. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009;50:1750-1755.
2. Clark PJ, Muir AJ. Overcoming barriers to care for hepatitis C. N Engl J Med 2012;366:2436-2438.